Free Trial
→ Trump’s Policies Are In Play—Here’s Where Smart Money Is Headed (From Darwin) (Ad)tc pixel

Cybin (OTCMKTS:CYBN) Shares Down 5.9% - Here's What Happened

Written by MarketBeat
September 25, 2025
Cybin logo with Medical background

Key Points

  • Cybin Inc.'s share price decreased by 5.9% to $6.04 during mid-day trading, with a trading volume significantly above the average at 1,055,340 shares.
  • The company has a market capitalization of $142.48 million and is focused on developing psychedelic-based therapeutics with its candidates currently in various stages of clinical trials.
  • Key products in development include CYB003 for treating major depressive disorders and CYB004 aimed at generalized anxiety disorders, highlighting Cybin's innovative approach in the biopharmaceutical sector.
  • Five stocks to consider instead of Cybin.

Cybin Inc. (OTCMKTS:CYBN - Get Free Report)'s share price traded down 5.9% during mid-day trading on Wednesday . The company traded as low as $6.02 and last traded at $6.04. 1,055,340 shares traded hands during trading, an increase of 189% from the average session volume of 365,273 shares. The stock had previously closed at $6.42.

Cybin Stock Performance

The firm has a market cap of $142.48 million, a price-to-earnings ratio of -31.79 and a beta of 0.68. The business's 50-day moving average is $7.05 and its 200-day moving average is $7.21.

Cybin Company Profile

(Get Free Report)

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cybin Right Now?

Before you consider Cybin, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.

While Cybin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.